NCT05921006

Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects

A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 98 (estimated)
• Sponsor: Nanjing Ruijie Pharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Randomized Study of RJ4287 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Doses in Healthy Volunteers

Conditions

• Drug Safety

Interventions

Type	Name	Description
DRUG	RJ4287	Oral，tablets，Once daily for 14 days
DRUG	Placebo	Oral，tablets，Once daily daily for 14 days

Timeline

• Start date: 2023-06-13
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2023-06-27
• Last updated: 2023-07-06

Locations

1 site across 1 country: China